Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Oncology
Kyowa Kirin invests in MEI Pharma’s blood-cancer drug
by Ryan Cross
April 18, 2020
| A version of this story appeared in
Volume 98, Issue 15
The Japanese drugmaker Kyowa Kirin will pay San Diego–based MEI Pharma $100 million up front and up to $583 million in milestone payments to develop and commercialize its experimental blood-cancer drug, MEI-401. The compound, a small-molecule inhibitor of phosphatidylinositol 3-kinase (PI3K) delta, is being tested in a Phase II study of follicular lymphoma and a Phase I study of B-cell malignancies. The firms will split costs and profits in the US, while Kyowa Kirin has exclusive rights to the drug everywhere else.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X